Gout Drug Reduces COVID-19 Related Risks
The Montreal Heart Institute (MHI) announced on January 22, 2021, that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. In patients with a proven diagnosis of COVID-19, colchicine reduced hospitalizations by 25%, the need for mechanical ventilation by 50%, and deaths by 44%.
Colchicine is used to prevent gout attacks (sudden, severe pain in one or more joints caused by abnormally high levels of a substance called uric acid in the blood) in adults, reports MedlinePlus.
The analysis of the 4,159 patients in whom a nasopharyngeal PCR test proved the diagnosis of COVID-19 has shown that the use of colchicine was associated with statistically significant reductions in the risk of death or hospitalization compared to placebo.
“Our innovative research program also proves that the Montreal Heart Institute can make rapid scientific breakthroughs in a way that is economically viable for patients by repurposing existing drugs,” commented Dr. Jean-Claude Tardif in an MHI press statement.
Last updated on January 25th, COLCORONA is a contact-less, randomized, double-blind, placebo-controlled clinical trial conducted in Canada, the United States, Europe, South America, and South Africa.